BiotechTube
Mediso

Mediso

Budapest, Hungary· Est.
mediso.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Mediso is an established, privately-held developer of sophisticated hybrid molecular imaging systems for both clinical and preclinical applications. Its core strength lies in integrated platforms like the AnyScan® TRIO (SPECT/CT/PET) and the cryogen-free nanoScan® PET/MRI, with a strategic focus on the growing theranostics and quantitative imaging markets. The company has demonstrated steady growth through product launches, FDA software approvals, and geographic expansion into key Western European and North American markets via subsidiaries and partnerships.

OncologyNeurologyCardiology

Technology Platform

Modular hardware and software platforms for hybrid molecular imaging. The AnyScan® platform (clinical) offers configurable SPECT, CT, and PET detector combinations. The nanoScan® platform (preclinical) includes PET/MRI, PET/CT, and SPECT/CT systems, featuring cryogen-free MRI technology. Both are unified by the proprietary InterView™ software suite for workflow, processing, and reporting.

Opportunities

The global expansion of theranostics creates strong demand for high-performance, quantitative SPECT/CT systems for treatment planning and monitoring.
In preclinical research, the shift towards translational biomarkers and the operational burden of cryogen management present a major opportunity for Mediso's cryogen-free, high-field PET/MRI systems.

Risk Factors

Intense competition from large, established multinational medical imaging corporations with greater resources and brand recognition.
Reliance on the capital expenditure cycles of hospitals and research institutions, which are vulnerable to macroeconomic and funding pressures.

Competitive Landscape

Mediso competes in clinical imaging with giants like Siemens Healthineers, GE Healthcare, and Philips. In the preclinical space, key competitors include Bruker, MR Solutions, and MILabs. Its strategy is to compete through technological differentiation (e.g., triple-detector SPECT, cryogen-free MRI), configurability, and a unified software platform, rather than on scale alone.

More companies in Diagnostics & Precision Medicine →More companies in Hungary →